PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers

被引：2
|
作者：
Stebbing, Justin [1 ]
Ellis, Paul [2 ,3 ]
Tutt, Andrew [4 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Oncol & Surg, London W12 0NN, England
[2] Guys & St Thomas NHS Trust, Dept Oncol, London, England
[3] Kings Coll Hosp, London, England
[4] Guys Hosp, Breakthrough Breast Canc Res Unit, Kings Hlth Partners AHSC, London SE1 9RT, England
来源：
FUTURE ONCOLOGY | 2010年 / 6卷 / 04期
关键词：
breast cancer; BRCA; PARP inhibitor; triple negative; POLY(ADP-RIBOSE) POLYMERASE; RESISTANCE; DNA; REPAIR; MUTATIONS; TUMORS; BRCA1;
D O I：
10.2217/FON.10.27
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：485 / 486
页数：2
相关论文
共 50 条
  • [1] Current perspectives on BRCA1- and BRCA2-associated breast cancers
    Phillips, KA
    INTERNAL MEDICINE JOURNAL, 2001, 31 (06) : 349 - 356
  • [2] Evidence That BRCA1- or BRCA2-Associated Cancers Are Not Inevitable
    Levin, Bess
    Lech, Denise
    Friedenson, Bernard
    MOLECULAR MEDICINE, 2012, 18 (09) : 1327 - 1337
  • [3] PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations
    Layman, Rachel M.
    Arun, Banu
    CANCER JOURNAL, 2021, 27 (01) : 67 - 75
  • [4] Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections
    Fountzilas, Elena
    Konstantopoulou, Irene
    Vagena, Andromahi
    Apostolou, Paraskevi
    Papadimitriou, Christos
    Christodoulou, Christos
    Tryfonopoulos, Dimitrios
    Manousou, Kyriaki
    Delimitsou, Angeliki
    Papamentzelopoulou, Myrto
    Fountzilas, Georgios
    Yannoukakos, Drakoulis
    Fostira, Florentia
    CLINICAL BREAST CANCER, 2020, 20 (02) : 152 - 159
  • [5] Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma
    Hamilton, LJ
    Evans, AJ
    Wilson, ARM
    Scott, N
    Cornford, EJ
    Pinder, SE
    Khan, HN
    Macmillan, RD
    CLINICAL RADIOLOGY, 2004, 59 (10) : 895 - 902
  • [6] Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
    Jan C. Drooger
    Bernadette A. M. Heemskerk-Gerritsen
    Nyrée Smallenbroek
    Cynthia Epskamp
    Caroline M. Seynaeve
    Agnes Jager
    Breast Cancer Research and Treatment, 2016, 156 : 557 - 566
  • [7] Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
    Drooger, Jan C.
    Heemskerk-Gerritsen, Bernadette A. M.
    Smallenbroek, Nyree
    Epskamp, Cynthia
    Seynaeve, Caroline M.
    Jager, Agnes
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (03) : 557 - 566
  • [8] PTEN alterations in sporadic and BRCA1- associated triple negative breast carcinomas
    Jones, Natalie
    Gros, Audrey
    Velasco, Valerie
    Dapremont, Valerie
    Brouste, Veronique
    Gastaldello, Bernadette
    Debled, Marc
    de Lara, Christine Tunon
    Bonnet, Francoise
    Barouk-Simoner, Emmanuelle
    Bubien, Virginie
    Venat, Laurence
    MacGrogan, Gaetan
    Longy, Michel
    Sevenet, Nicolas
    CANCER GENETICS, 2022, 264 : 8 - 15
  • [9] Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1- associated triple-negative breast cancers
    Domagala, Pawel
    Hybiaki, Jolanta
    Rys, Janusz
    Byrski, Tomasz
    Cybulski, Cezary
    Lubinski, Jan
    ONCOTARGET, 2016, 7 (42) : 68662 - 68673
  • [10] BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness
    Domagala, Pawel
    Hybiak, Jolanta
    Cybulski, Cezary
    Lubinski, Jan
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (07) : 1545 - 1550
12345